17 results
Lisinopril - ACE inhibitor used for the treatment of hypertension and heart failure. 3rd most prescribed
Lisinopril - ACE ... inhibitor used for the treatment ... #Pharmacology #Lisinopril ... Prinivil #Qbrelis #ACEI
Heart Failure (HFrEF) Treatment - GDMT for stage C 

For patients with Heart Failure with REDUCED
Failure (HFrEF) Treatment ... recommended by the ACC ... /ambcarerx #CHF ... #HFrEF #Pharmacology ... #Management #Treatment
Medications Used in Hypertensive Emergencies
Vasodilators: Hydralazine, Nitroglycerin, Sodium nitroprusside 
Calcium Channel Blockers: Clevidipine, Nicardipine
ß-Blockers: Esmolol, Labetalol,
Labetalol, Metoprolol ACE ... Medications #Management #Treatment ... #Pharmacology #
Migraine - Preventative Treatments

 • Anticonvulsants: *Topiramate, *Sodium valproate, Gabapentin, Pregabalin
 • Antidepressants: Amitriptyline, Venlafaxine, Duloxetine,
- Preventative Treatments ... Beta-blockers, ACE ... #Preventative #Treatment ... prophylaxis #prevention #pharmacology
Heart Failure Medications Summary
Inhibitors of the Renin-Angiotensin System:
 • ACE Inhibitors: Benazepril, Captopril, Enalapril, Lisinopril, Quinapril,
Renin-Angiotensin System: • ACE ... #Medications #CHF ... #cardiology #pharmacology
Management of Diabetes Mellitus in Patients With CKD

1. Monitor for changes in BP, serum creatinine, &
the dose of an ACEi ... Continue ACEi or ... initiation of treatment ... Statements: All ... evidence-based pharmacologic
AACE/ACE 2016 Postmenopausal Osteoporosis Treatment Algorithm

Evaluate for causes of secondary osteoporosis

Correct calcium/vitamin D deficiency and address
AACE/ACE 2016 Postmenopausal ... Osteoporosis Treatment ... • Recommend pharmacologic ... Postmenopausal #Treatment
Heart failure with Reduced Ejection Fraction (HFrEF)
Clinical Presentation
1. Typical symptoms: dyspnea, orthopnea paroxysmal noctumal dyspnea, fatigue,
81% for acute HF ... endomyocardial biopsy Pharmacology ... : • ACE Inhibitors ... management #cardiology #pharmacology ... #sCHF
Differentiation Syndrome in APML
Epidemiology:
 • Incidence: common in APL (2-48% depending on the study)
 • Triggers:
Incidence: common in APL ... Triggers: ATRA treatment ... sepsis), PE, DAH, CHF ... Renal Failure Treatment ... diagnosis #management #hematology
Veltassa (Patiromer) 
MECHANISM: Potassium Binder 
INDICATION: Treatment of Hyperkalemia 
FORMULATION: Powder for oral suspension 
DOSING: 8.4
INDICATION: Treatment ... patients with CKD, HF ... ACE inhibitors, ... #Hyperkalemia #Pharmacology